The cause of Guillain-Barré syndrome elucidated

Guillain-Barré syndrome is a rare disease in which the immune system attacks the peripheral nerves. Those affected suffer from muscle weakness and paralysis. A research team led by ETH Zurich has now elucidated the mechanism of this autoimmune reaction. Patients with Guillain-Barré syndrome (GBS) suffer from a rare and diverse disorder of the peripheral nervous

Read More


UN agencies warn women and newborns bearing the brunt of the conflict in Gaza: WHO confirms

Women, children and newborns in Gaza are disproportionately bearing the burden of the escalation of hostilities in the occupied Palestinian territory, both as casualties and in reduced access to health services, warn the United Nations Children’s Fund (UNICEF), the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), the United Nations

Read More


Researchers of Tel Aviv University use Smartwatches to Measure Safety of COVID Vaccine

Tel Aviv University researchers monitored the physiological data of close to 5,000 Israelis over two years In a first-of-its-kind study, researchers at Tel Aviv University equipped close to 5,000 Israelis with smartwatches and monitored their physiological parameters over two years. Of those monitored, 2,038 received the booster dose of the coronavirus vaccine, allowing the researchers

Read More


Mapping the hurdles for the clinical applications of ATMPs and Clinical trials of combined ATMPs: two forthcoming single-stage Horizon Europe framework programs

1) Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs) Deadline model single-stage Planned opening date 12 January 2023 Deadline date 13 April 2023 17:00:00 Brussels time ExpectedOutcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative,

Read More


Strengthening the European translational research ecosystem for advanced therapy medicinal products (ATMPs) for rare diseases. An open Horizon Europe Framework Program for consortia.

Single stage with dead-line 15 march 2023 ExpectedOutcome: Research and innovation (R&I) actions to be supported under this topic must work towards results that contribute to all the following expected outcomes. Scope: There are over 7 000 rare diseases resulting in 30 million patients1 in Europe with a rare disease. Globally more than 300 million patients2 are

Read More


Nearly 13 Percent of COVID-19 Hospitalized Patients Had Serious Neurologic Symptoms

Overwhelming evidence shows that infection with severe acute respiratory syndrome (SARS-CoV-2) causes dysfunction of multiple organ systems, including the nervous system. Neurologic symptoms are frequently reported even in patients with mild illness and for some, these neurologic symptoms may persist as part of long-haul COVID. To describe the prevalence, associated risk factors and outcomes of

Read More


Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain

Survivors of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection frequently experience lingering neurological symptoms, including impairment in attention, concentration, speed of information processing and memory. This long-COVID cognitive syndrome shares many features with the syndrome of cancer therapy-related cognitive impairment (CRCI). Neuroinflammation, particularly microglial reactivity and consequent dysregulation of hippocampal neurogenesis and oligodendrocyte lineage cells,

Read More


A NIH researchers study shows SARS-CoV-2 can persist in the body as long as 230 days

In what they describe as the most comprehensive analysis to date of the SARS-CoV-2 virus’s distribution and persistence in the body and brain, scientists at the U.S. National Institutes of Health said they found the pathogen is capable of replicating in human cells well beyond the respiratory tract. The results, released online Saturday in a

Read More